Bristol/Teva “Authorized” Generic Agreement Approved By FTC
This article was originally published in The Pink Sheet Daily
Executive Summary
A settlement allowing Teva to launch generic carboplatin in June is not anti-competitive, the Federal Trade Commission says. The agreement encourages price competition and gives Teva an incentive to launch under an ANDA as soon as possible, FTC says.
You may also be interested in...
“Authorized” Generics Fight Moves To Capitol Hill, FTC
Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.
“Authorized” Generics Fight Moves To Capitol Hill, FTC
Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.
Corixa Names Marketing VP
Corixa has named former Bristol-Myers Squibb U.S. Oncology Division Director Christof Marre to the newly created position of VP-marketing.